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Drug treatment of kidney clip-induced hypertension in rats. 
Peroxidase tracer spot frequency in rat aorta after chemically induced apoptosis. 
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Kidney clip-induced hypertensive rats were treated with two classes of anti-hypertensive drugs: 
beta-blockers and calcium channel blockers. Their blood pressures were monitored for several 
months, as were those of normotensive control rats. The hypertensive rats responded to treatment 
with drops in blood pressure, in some cases of greater than 70 mmHg. The variability of blood 
pressure was found to be similar in all three groups of rats. 
Horseradish peroxidase spot size experiments were performed on rats that had been treated with 
cytotoxic agents to induce apoptosis. Spot frequency was observed to be lower in these treated 












Chapter 1:  The effect of beta blocking and calcium channel blocking anti-hypertensive 
drugs on kidney clip-induced hypertensive rats 
 
1.1: Introduction 
Another student in the lab, Dr. Jimmy Toussaint, had investigated the role of aquaporin-1 
(AQP1) in the progress of atherosclerosis, a topic addressed in great detail in (26). One aspect of 
that work was the effect of hypertension on the expression of AQP1 in rat endothelial cells; it 
increased such expression. As one of several controls, he sought to induce hypertension in eight 
rats, reverse the hypertension with drugs, and then measure aquaporin-1 expression. To this end, 
he performed the two clip, one kidney Goldblatt procedure on eight male Sprague Dawley rats. 
The purpose of this control experiment was to rule out the possibility that some aspect of this 
surgery aside from the elevated blood pressure it induces had an independent effect on AQP1 
expression. All animal work was approved by the Institutional Animal Care and Use Committee 
(IACUC) of City College.  In this procedure, described in Frei (6) and Mohring (15) the 
abdominal cavity of the rat is opened and a silver clip with a gap width of 200 microns is placed 
on the renal artery. This restricts blood flow to the kidney and induces various hormonal changes 
that eventually result in hypertension. Six of the animals developed hypertension, and it was my 
goal to medicate them to lower their blood pressure. 
Toussaint had already performed a version of this experiment in which the drug of choice was 
captopril, an angiotensin converting enzyme (ACE) inhibitor. In that study, hypertensive rats that 
had been restored to normotensive with captopril were found to have far lower levels of AQP1 
than both healthy, normotensive, untreated rats and sham-operated rats (in the sham operation, 
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every step of the Goldblatt procedure is performed except for placement of the arterial clip). 
Toussaint therefore concluded that the Captopril had an independent effect on AQP1. He later 
conducted a literature review and found published evidence (31) of another ACE inhibitor’s 
negative effect on AQP1 expression (26). 
1.2: Materials and Methods 
In light of these considerations, drugs of different classes were selected for this batch of six 
hypertensive rats. The batch was subdivided into two groups, each including one rat with blood 
pressure above 200 mmHg and two with blood pressure of approximately 160 mmHg.  One 
group was treated with generic atenolol (Teva), a beta blocker, and the other with diltiazem 
(Teva or Mylan), a calcium channel blocker. 
The goal, then, was to lower these rats’ blood pressures. Three were given generic atenolol, a 
beta blocker in a dose range of  10 to 140 mg/kg/day. The other three were given generic 
diltiazem, a calcium channel blocker in a dose range of 40 to 200 mg/kg/day. The doses were 
increased gradually, and all rats were monitored closely by researchers and animal facility staff 
for signs of acute illness or distress. The drugs were purchased from local retail pharmacies in 
pill form and crushed and ground into powder in a mortar and pestle. Initially, both drugs were 
added to the rats’ drinking water. To achieve the intended dose, the rats’ daily water intake was 
measured over several days and the concentrations adjusted accordingly. Unfortunately, as noted 
in (6), rats have been known to avoid aqueous diltiazem solution, even at the risk of dehydration. 
Indeed, such was the case in our study, leading to two problems: the rats became dehydrated, and 
they did not receive the intended dose of diltiazem. Additionally, at high enough doses, even the 
atenolol solution was avoided, leading to some dehydration in that group as well. At various 
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points in the study, dehydrated rats were given Pedialyte (Abbot Labs), a sweetened cherry 
flavored beverage fortified with electrolytes, as a short-term antidote to dehydration.  
To combat the less acute but more fundamental problem of how to have the rats ingest the drug, 
we decided to mix the diltiazem into a treat for the rats. On the advice of the institutional 
veterinarian, we initially selected peanut butter (Associated brand, purchased at a local 
supermarket) as this treat. However, this proved ineffective, i.e. the rats ate either some or none 
of the peanut butter and could not be assumed to be receiving the intended dose. Next we tried 
replacing the peanut butter with Bio-serv bacon flavored Transgenic Dough Diet, a calorie dense 
diet supplement or replacement with the texture of cookie dough that is designed to stimulate 
appetite. This proved much more popular with the rats, meaning they almost always finished the 
entire portion, and had the added benefit of countering weight loss. See (15) for other evidence 
of lower body weight in hypertensive rats. Eventually, all rats in the calcium channel blocker 
group and one in the beta blocker group received this Transgenic Dough Diet. 
Another problem encountered was partial response. That is, blood pressure decreased in all 
animals treated with the initial dose but did not reach normotensive levels. The first step taken to 
address this problem was to simply increase the dose, and for the beta blocker group rats this 
eventually proved sufficient. However, in the calcium channel blocker group, blood pressure 
remained above normotensive levels even at higher doses, and so a second drug in the same 
class, amlodipine (Camber Pharmaceuticals), was added to those rats’ diets in a dose ranging 
from 1 to 10 mg/kg/day. Again, the dose was increased gradually, and all animals were closely 
monitored for signs of acute illness or distress. 
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Systolic blood pressure was measured by a non-invasive inflatable tail cuff method 
(ADInstruments). We did not monitor diastolic blood pressure, because these readings are less 
accurate and less reproducible by tail cuff measurements. 
1.3: Results and Discussion 
The graphs below represent systolic blood pressure recordings taken before the procedures and 
approximately once a week between the surgery and Toussaint’s AQP1 experiment, which 
involved euthanizing the rats. The measurements were taken by Toussaint and Chirag Raval. In 
all the graphs, the first measurement was taken before the surgery. The surgeries were performed 
between September 4 and September 11. The six hypertensive rats were first given medication in 
late October and their doses were gradually increased over subsequent weeks and months. The 
values reported are averages of 4 to 15 measurements taken in one sitting, with error bars 
representing positive and negative spread about the mean. For the control rats (figs. 1.7-8), after 
6 consecutive sets of post-surgical measurements all showed normal blood pressure, no more 
measurements were recorded until just prior to euthanasia in the next stage of the experiment. 
There is also a month-long gap between the last two measurements in figure 1.6. This represents 
a time when that particular rat showed various signs of illness, including low body weight and 






Figure 1.1: Blood pressure time course of rat A 
Surgery: 9/11 





Figure 1.2: Blood pressure time course of rat B 
Surgery: 9/11 




Figure 1.3: Blood pressure time course of Rat C 
Surgery: 9/12 




Figure 1.4: Blood pressure time course of Rat D 
Surgery: 9/12 





Figure 1.5: Blood pressure time course of Rat E 
Surgery: 9/10 






Figure 1.6: Blood pressure time course of Rat H 
Surgery: 9/12 







Figure 1.7: Blood pressure time course of Rat F 
Surgery: 9/4 





Figure 1.8: Blood pressure time course of Rat G 
Surgery: 9/10 




First note the different baseline blood pressure levels recorded about one month after surgery, 
before initiation of drug treatment. The two controls in this study underwent the full Goldblatt 
procedure, including placement of the clip, but failed to develop hypertension. Additionally, 
among the hypertensive animals, two were severely hypertensive (systolic blood pressure (SBP) 
> 200 mmHg) and four only moderately (SBP ~ 160 mmHg). Slight errors (on the order of tens 
of microns) in the gap spacing of the clips, as well as small variations in renal artery diameter 
among the animals, can go a long way toward explaining this variation, which has been found by 
other investigators (6, 9). Frei, for example, reports that only 60% of his kidney-clipped rats 
developed hypertension, and among the hypertensives there was a 12 to 14 point spread about 
the mean systolic blood pressure (6). It is reasonable to conjecture that, as the blood pressure 
increase is induced by constriction of the renal artery, variations in the gap width of the clip and 
the diameter of the vessel, which lead to variations in the level of constriction, would in turn 
cause variations in the level of hypertension. Also consider rat weight at the time of surgery, at 
least the most intuitively obvious indicator of vessel diameter. The graph below plots ultimate 
blood pressure as a function of rat weight at surgery. While there is a good deal of scatter and the 
total number of subjects is a rather low eight, the graph is at least suggestive of a correlation. 
Unfortunately, information on the deviation of the actual gap width of the clips from the 
attempted 200 microns is unavailable. It could be instructive to plot that data against ultimate 
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levels of hypertension and see whether it is a clearer predictor than rat weight. 
 
Figure 1.9: blood pressure versus rat weight at surgery 
 
Next, note the initial drop in blood pressure shortly after initiation of drug treatment at the end of 
October in all six cases. These drops, in all cases except case C, were not all the way down to 
normotensive levels. Also, in the diltiazem group, these decreases were followed shortly by 
relapses, as more diltiazem was added to the rats’ drinking water (in attempt to lower blood 
pressure still further, to normotensive levels) and they stopped drinking. 
Some results seem almost obvious upon a close reading of the literature, others are less readily 
apparent but help to explain how previous experiments have been designed, and a few are truly 
novel. First, all rats responded to drug treatment at typical doses with decreases in blood pressure 
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in good agreement with previously reported results. Next, rats do tend to avoid diltiazem, as well 
as atenolol at high enough doses, even at the risk of dehydration. It should be pointed out, 
however, that this study was not the first to attempt to administer diltiazem via drinking water. 
This study, as mentioned above, used pill forms of the drugs purchased from a local pharmacy, 
mainly for reasons of financial expense. These pills contain, by weight, far more inactive 
material than active (by a factor of approximately 2 to 40, depending on the drug). First there is 
the remote chance that so-called inactive ingredients actually have some effect that may 
introduce artifact. More troubling, however, is the tendency of the starches and other components 
to precipitate out of solution. One hopes that the precipitate contains only fillers, coloring and 
such and that all of the medically active substance remains dissolved in solution, but this is 
difficult to verify and, indeed, was not verified for this study. Another decision made for reasons 
of cost was to deliver the drugs via drinking water, as injecting the solution directly into the 
animals’ mouths would have required either recruiting trained animal handlers or investing in 
training the researchers involved in the study. In addition to the dehydration problem mentioned 
above, the rats grew over the course of the study and began to drink more than earlier 
measurements indicated. Further, variations in severity of the rats’ renal hypertension, a disease 
known to cause thirst (15), also led to changes in water intake. These factors help explain why 
other groups went to all the trouble and expense of obtaining pure forms of the drug from 
chemical suppliers and administering them to their animals by the more standardized method of 
daily oral injection. These concerns must certainly be taken into account in planning future work. 
One finding bears mentioning, because it was not observed in a review of the literature on 
treatment of hypertension in rats with these drugs. This study found that, at high enough doses 
(which obviously did not prove lethal, or even immediately harmful), drops in blood pressure of 
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more than 70 points were possible with both atenolol and the diltiazem/amlodipine combination. 
One rat was even restored all the way from severely hypertensive to normotensive, although that 
piece of data should be treated with great care, as that rat exhibited other signs of illness for most 
of the last two months of the study, and its blood pressure proved unusually difficult to measure. 
1.4: A note on blood pressure variability 
After completing the above blood pressure study, our group learned, in private communication 
with pharmaceutical industry researchers, of interest in not only the level of blood pressure but 
also the level of variation of blood pressure in drug treated hypertensive subjects. This is in 
addition to the well-known problem of error in indirect blood pressure measurement. Since they 
have already studied spontaneously hypertensive rats, they are especially interested in kidney-
clipped hypertensive rats, as these are not genetic mutants and are, therefore, considered more 
representative of the general rat population. Millar-Craig (14), referring to human patients, noted 
this issue in 1978, and our experience in this study confirmed that the problem has not gone 
away since. Beyond this, there is a tendency of blood pressure to vary as function of different 
factors, such as season (2) and time of day (12). In this study, since measuring variability was not 
the original goal, no precautions were taken to ensure that measurements were consistently taken 
at the same time of day. Depending on the researchers’ schedules and how long it took for the 
rats to become sufficiently calm and sedentary to allow for measurement, the recordings were 
taken in the morning, afternoon, or evening. 
 Obviously, some understanding of how blood pressure fluctuates is necessary for effective 
monitoring and treatment of hypertension. In addition to that, however, increased variation in 
blood pressure is a known indicator of hypovolemia (22), and decreased variation may be 
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important as a predictor of kidney disease (5), indicating that this measure may be an important 
independent health factor.  Clearly, then, if the goal of drug therapy of hypertension is to return 
patients to the level of health and functioning of normotensive patients, then comparing blood 
pressure variation in untreated normotensives and treated hypertensives is a reasonable next step 
after bringing the mean pressures of the two groups within the same range. 
To this end, we retrospectively examined the variability of blood pressure levels in our three 
groups of rats: beta blocker treated (n=3), calcium channel blocker treated (n=3) and 
normotensive control (n=2). Following Balansard (1) and others, we calculated coefficients of 
variability (CV) for the eight series of measurements. This measure is simply the standard 
deviation divided by the mean. Included were all data for the normotensive rats and data 











Table 1.1 Coefficients of variation for treated and untreated rats 




Rat A, Figure 1.1 
0.0558 
Rat D, Figure 1.4 
0.136 
Rat F, Figure 1.7 
0.133 
Rat B, Figure 1.2 
0.163 
Rat E, Figure 1.5 
0.0851 
Rat G, Figure 1.8 
0.0573 
Rat C, Figure 1.3 
0.0580 
Rat H, Figure 1.6 
0.190  
 
A cursory look at the above table brings a single word to mind: noise. The two normotensives 
have widely divergent CV’s, and four of six of the hypertensive CV’s fall within or just outside 
(0.133 versus 0.136) that range. One reassuring entry is the 0.190 for one of the calcium channel 
blocker treated rats. This rat’s high variability corresponds to the observations and experience of 
all researchers involved in the project. It exhibited dehydration, low body weight, and other signs 
of ill health for much of the study; its blood pressure proved far more difficult to measure than 
those of the other rats; and a plot of its blood pressure measurements over time (figure 1.6, rat H) 
looks almost sinusoidal. 
Also reassuring is a look at the literature on human blood pressure measurement. Peixoto (21) 
took indirect blood pressure measurements of hemodialysis patients and included those currently 
taking antihypertensive drugs as long as their drug regimens remained unchanged for the 
duration of the study. He found CV’s  based on their systolic blood pressure ranging from 0.075 
all the way to 0.167, depending on the measuring procedure. Mancia (13) excluded all patients 
24 
 
with major diseases aside from hypertension, excluded those who had been treated with 
antihypertensive drugs, measured blood pressure by a direct invasive technique, and used a study 
population of 89 people. These precautions yielded long term systolic blood pressure variability, 
as measured by CV, of 0.08 to 0.10. (As a point of interest, the lower variability was seen in the 
severely hypertensive group.) Musso (16) notes that office sphygmomanometry is subject to 
“error as high as 38 mmHg.” And remember that rats, even in a warm, dark and quiet 
environment, cannot be expected to hold still, although we did attempt to encourage this by 
providing the rats with a quiet, warm, and dark environment for approximately an hour before 
and during the measurement routine. 
In light of these considerations, the values in the table above , while they unfortunately fail to say 
anything definitive about the differences in blood pressure variability in normotensive and 
treated hypertensive rats due to the small sample size, do suggest that the methods selected for 
monitoring the rats’ blood pressures yielded results well within reported ranges. 
One methodological point does bear mentioning. The coefficient of variability is essentially a 
normalized standard deviation. As such, it indicates of how far observations vary from the 
overall mean. It seems a perfectly appropriate (if somewhat blunt) measure for the medical 
studies cited above: the blood pressure is not expected to change, and this value quantifies the 
deviation from that expectation. Similarly, one can imagine a study similar to ours in which rats 
are given a constant dose of an antihypertensive drug, except, perhaps, for adjustments to 
account for weight changes. There too, we would expect a constant mean with some variation, 
and we could measure this variation. However, in our case, the rats’ doses were regularly 
increased until they became normotensive, or as close as we considered possible, at which point 
they were euthanized in the next stage of the experiment, rather than being maintained at that 
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dose and monitored for an extended period of time. There were also points at which the rats’ 
doses effectively decreased, for various reasons described above, e.g. they stopped eating or 
drinking the drug-containing substance. If one were to partition the data into different regions 
based on dose, regions in which one would expect a constant mean, one would in most cases find 
only one or two sets of measurements between dose changes, for the following reasons. 1) 
Measurements were taken once or twice a week, while dose changes often took a number of days 
to implement due to rat taste preferences. 2) The experimental protocol called for rat euthanasia 
to be carried out approximately one week after a stable lower blood pressure had been attained, 
before the rats reached a critical age and weight. This did not allow us the time necessary to 
monitor the rats’ blood pressures during extended drug treatment at a constant dose. 
In light of this, if the treated rats had shown greater variability than the normotensives, it would 
be unwarranted to ascribe this increase to the drugs. However, the treated rats, with the exception 
of one with other health problems, showed variability quite similar to that of the normotensives 
(slightly smaller for the beta blocker group and slightly larger for the healthy rats in the calcium 
channel blocker group). This suggests two ideas. First, CV may be a fairly crude measure of 
variability. Second, and more interestingly, the variability introduced by an antihypertensive 
drug regimen in a small sample set seems to be only slightly greater than that of the ordinary 
dynamic nature of physiology. One also needs to assess the effect of measurement error, but 
recall Mancia’s CV’s of 0.08 to 0.1 even when measuring blood pressure directly. 
The portion of the experiment that seeks to quantify AQP-1 expression in these rats’ aortic 





If we were to set out to quantify blood pressure variability, we would design the study 
differently. We would use the same method of hypertension induction and probably the same 
drugs to treat it. However, we would be careful to consistently measure blood pressure at the 
same time of day. Even more importantly, we would decide on a dose, tune it according to rat 
response, and then maintain the rats at that dose for a number of weeks or months, during which 















Chapter 2: HRP spot frequency in rat aorta after chemically induced apoptosis 
Introduction 
For decades now, researchers such as Chuang (4), Stemerman (25), and Shou (24) have used 
tracer studies to characterize mass transfer into artery, and especially aorta, walls. They have 
found focal leakage. That is, intense spots of accumulated tracer tend to form rather than (or in 
addition to, in the case of small tracers) a uniform darkening. Some have used tagged low-
density lipoprotein (LDL); others have used Evans Blue albumin or horseradish peroxidase. The 
peroxidase molecule, while significantly smaller than the 22 nanometer diameter LDL, is, at a 
diameter of 6 nanometers, far larger than water and is believed to pass through the endothelial 
layer and into the artery wall far more easily through so-called leaky junctions, or unusually wide 
gaps between cells, as proposed by Weinbaum (29). For a more extensive review of the literature 
on spot size studies of mass transfer into artery walls, see Yu (32). 
Materials and Methods 
All procedures were IACUC approved. The control experiment followed the method of Yu, with 
chemicals and other materials sourced from the same suppliers, with one modification. As Yu 
reports (32), 
“To prepare the tracer, we dissolve 0.58g NaCl in 100 ml distilled water; then add 0.024 g HRP (for a 300 
g rat) in 1mL normal saline. All procedures are IACUC approved.  
30 mg Pentobarbital Sodium/kg body weight rat in a 1% solution (100 mg Pentobarbital Sodium in 10 ml 
of distilled water, shaken gently) by intraperitoneal injection anesthetizes the rat. We shave the rat’s left leg, dissect 
it and cannulate the left femoral vein and artery… We intubate the rat by attaching its trachea to a rodent 
respirator…  
We inject 1ml HRP and 0.5 - 1ml Heparin (5000 units/1 ml, Elkins-Sinn Inc. NJ). At 0.5, 1, 2… min blood 
circulation, an overdose of Pentobarbital Sodium sacrifices the rat. After flushing with 10ml PBS (Phosphate 
Buffered Saline; Sigma) and then perfusion-fixing the vessels in situ at room temperature with 1% Glutaraldehyde 
(Sigma) (1 ml 50% Glutaraldehyde in 50 ml PBS) introduced into the carotid vein and artery and draining from the 
femoral arteries, we excise the thoracic aorta… We prepare the excised vessels for examination by peeling away the 
connective tissues and the adventitia, further fix them in 1% Glutaraldehyde for 1 hour [or overnight], rinse with 
PBS three time to wash out the fixative and run the HRP-DAB reaction to develop the tracer spot. We dissolve 
0.045 g DAB in a solution of 5 ml 0.3M Tris (0.182 g Tris (MW=121.1) in 5 ml H
2
O) in 25 g distilled water, add 20 
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, followed by 1M HCl to adjust the pH to 7.0~7.4 and then place the tissue in it. The DAB solution is 
changed after 30 min and allowed to continue for another 30 min. The tissue is washed with PBS solution and 
prepared on slides for en face examination with an Olympus BX51 light microscope. The reaction product is brown, 
and so the leak is a brown spot. Since HRP can slowly penetrate normal junctions, focal spots coexist with diffuse 
staining as in (14). We count the number of HRP spots by eye and measure the area of each piece of tissue. We then 
calculate the leakage frequency” [in spots per square millimeter].  
  
The modification in the experiments reported here is that the rats were given a larger 
initial dose of pentobarbital anesthetic of 60 mg/kg. In the apoptosis experiment, the rats were 
given 5 micrograms (ug) per kilogram of body weight of tumor necrosis factor alpha (TNFA) 
and 0.75 mg/kg of cycloheximide, both purchased from Sigma Aldrich, intravenously through 
the femoral vein. The rats were also given periodic booster doses of pentobarbital, based on 
response to paw-pinch tests and breathing rate, to keep them unconscious over the course of this 
longer experiment. In one experiment reported here, the drugs were injected in 4 equally divided 
boluses over half an hour. Since that method appeared to cause respiratory distress, it was 
rejected in the next 2 experiments in favor of continuous infusion, also over half an hour, which 
seemed to cause less distress. On the advice of another researcher, Dr. Limary Cancel, who had 
performed similar experiments on aortic endothelial cell monolayers, we allowed the drugs to 
circulate for 4 hours to take effect. We then performed the standard HRP experiment (see above). 
The images below are photographs taken with an Olympus consumer-grade digital camera 
mounted on an Olympus BX51 optical microscope. The magnification of the microscope was 
100x and that of the camera's zoom lens 3x. The images were further enlarged in the process of 
publishing them in this document. 
  
Results and Discussion 
We were concerned about the short biological half life of TNFA. Zahn (33) reports it as 5-8 
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minutes at a dose of 2 ug/kg administered to rats over half an hour and 30 minutes at 10 or more 
ug/kg. However, we decided to proceed, on the thinking that, though the drug may be eliminated 
fairly quickly, the damage it does may not be completely repaired in 4 hours. 
The images below show control HRP spots at circulation at circulation times of 30, 60, and 120 
seconds. The 4 minute experiment was not attempted, because other researchers (4, 32) have 
reported nearly uniform leakage at that circulation time. Also below are images of HRP spots in 
apoptosis-induced rat aortas. As the images demonstrate, the staining in the apoptosis-induced 
samples (figures 2.4, 2.6, 2.8, 2.10) is much fainter than that in the controls (figures 2.1, 2.2, 2.3, 
2.5, 2.7, 2.9). Both the spots and the background appear much lighter. It was for this reason that 
we did not attempt a 30 second experiment; we feared that the spots would not be visible enough 
to count in order to determine their frequency. We conjectured that a possible cause of this faint 
staining could be the deteriorating overall health of the animal over the course of the experiment, 
which took at least four hours longer than the control experiment. During the entire course of the 
experiment the animal was anesthetized with pentobarbital, a drug whose effective dose (60 
mg/kg delivered by intraperitoneal (IP) injection in this study, in line with our Institutional 
Animal Care and Use Committee’s recommendations) is within a factor of two of its mean lethal 
dose (120 mg/kg IP (34)). The American Veterinary Medical Association recommends a 
euthanizing dose of three times the anesthetic dose for rodents (35). The animals' heart and 
breathing rates were both observed to decrease as the experiment continued, and it is reasonable 
to assume that blood pressure may have also, which would have decreased the force driving 
solute into the aorta wall. If this experiment were to be repeated, it might be helpful to introduce 
the drugs via a tail vein cannulation instead of a femoral cannulation. This is a more difficult 
technique, but it is far less invasive and, therefore, requires less anesthesia. This might allow data 
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collection from a healthier animal. 
The frequency of the control HRP spots was found to be 0.80 spots per square millimeter of aorta 
(9 rats) surface, in good agreement with Yu's result of 1.04 (35 rats) (32). In the apoptosis 
experiments, the frequency was found, in direct contradiction of our prediction, to be a lower 
0.46 (3 rats). One possible explanation would be the declining health of the animal treated with 
anesthetic doses of pentobarbital for a number of hours, as discussed above. Another possible 
cause is the toxicity of the chemical treatment. Although Zahn (33) reports no toxicity in rats 
treated with doses of TNFA up to 100 times higher than ours, our dose of cycloheximide was 
half of the lethal dose (17, 28). Still another has to do with the short half life of TNFA (on the 
order of minutes). We did not attempt to predict how long it should take for a rat's aortic 
endothelium to be restored from especially leaky (the condition expected as a result of the 
chemical treatment) to typically leaky (the undisturbed state, once the chemicals have been 
cleared and their effects neutralized), but one thing is clear from the value of the half life: after 4 









Figure 2.2: 30s control HRP spot 





Figure 2.3: 60s control HRP spot 
 






Figure 2.6: apoptosis 60s HRP spot 




Figure 2.7: 120s control HRP spot 
 




Figure 2.9: 120s control HRP 
 




In our study, rat aortas exhibited, paradoxically, a lower HRP spot frequency when the rats were 
subjected to apoptosis-inducing chemical treatment. However, we suspect that this result may be 
an artifact of the experimental procedure and that the hypothesis that apoptosis leads to a higher 
spot frequency still warrants investigation. 
For future work, in addition to the above suggestion for mitigating the anesthesia effects, there 
are several ways to test the hypothesis that inducing apoptosis increases spot frequency. One 
would be to use TNFA in combination with another drug, as shown by Zahn (33) to increase 
TNFA's half life. Another would be to use polyethylene glycol-coated TNFA, which Tsutsumi 
(27) has shown also has a longer half life than native TNFA. A third option, one currently under 
consideration, would be to use a cytotoxic agent with a naturally longer half life. The anti-tumor 
drug Paclitaxel is one such drug, and we are planning experiments using it. 
Further, it would be useful to run several experiments with only TNFA and several with only 
cycloheximide. This could help us tease apart their independent effects, both on spot frequency 












1. Balansard P. [Blood pressure variation]. Archives des maladies du coeur et des vaisseaux. 
Pratique. 1987 Jun;80(6):999-1004. PubMed PMID: 3117002. 
2. Brennan PJ. Seasonal variation in arterial blood pressure.. BMJ. British medical journal 
(Clinical research ed.). 1982 Oct;285(6346):919-923. 
3. Cheek, D. B., C. D. West and C. C. Golden (1957). "The distribution of sodium and 
chloride and the extracellular fluid volume in the rat." J Clin Invest 36(2): 340-51. 
4. Chuang P, Cheng, J., Lin, S., Jan, K., Wang, D., and Chien, S. Macromolecular transport 
across arterial and venous endothelium in rats: studies with evans blue-albumin and 
horseradish peroxidase. Arteriosclerosis Arteriosclerosis: 188-197, 1990. 
5. Davidson MB. Association of Impaired Diurnal Blood Pressure Variation With a 
Subsequent Decline in Glomerular Filtration Rate. Archives of internal medicine (1960). 
2006 Apr;166(8):846-852. 
6. Frei . Glomerular hemodynamics of the clipped kidney: effects of captopril and diltiazem. 
The Journal of pharmacology and experimental therapeutics. 1992;263(3):938. 
7. Greischel, A. and G. Zahn (1989). "Pharmacokinetics of recombinant human tumor 
necrosis factor alpha in rhesus monkeys after intravenous administration." J Pharmacol 
Exp Ther 251(1): 358-61. 
8. Grellet . Diltiazem and left ventricular hypertrophy in renovascular hypertensive rats. 
Hypertension  (Dallas, Tex. 1979). 1988;11(6):495. 
9. Han P. The combination of atenolol and amlodipine is better than their monotherapy for 
preventing  end-organ damage in different types of hypertension in rats. Journal of 
Cellular and Molecular  Medicine. 2009 Apr;13(4):726-734. 
10. Imai H. Renin-angiotensin system plays an important role in the regulation of water 
transport in the peritoneum. Advances in peritoneal dialysis. 2001;17:20-4. PubMed 
PMID: 11510275. 
11. Korzekwa, A., S. Murakami, I. Woclawek-Potocka, M. M. Bah, K. Okuda and D. J. 
Skarzynski (2008). "The influence of tumor necrosis factor alpha (TNF) on the secretory 
function of bovine corpus luteum: TNF and its receptors expression during the estrous 
cycle." Reprod Biol 8(3): 245-62. 
12. Lemmer . Circadian blood pressure variation in transgenic hypertensive rats. 
Hypertension (Dallas, Tex. 1979). 1993;22(1):97 
38 
 
13. Mancia . Blood pressure and heart rate variabilities in normotensive and hypertensive 
human beings. Circulation research. 1983;53(1):96. 
14. Millar-Craig . Circadian variation of blood-pressure. The Lancet (British edition). 
1978;311(8068):795. 
15. Mohring . Effects of saline drinking on malignant course of renal hypertension in rats. 
The American journal of physiology. 1976;230(3):849. 
16. Musso . Reproducibility of ambulatory blood pressure monitoring. Blood pressure 
monitoring. 1996 Apr;1(2):105-109. PubMed PMID: 10226210.  
17. Nagami, K., Y. Kawashima, H. Kuno, M. Kemi and H. Matsumoto (2002). "In vitro 
cytotoxicity assay to screen compounds for apoptosis-inducing potential on lymphocytes 
and neutrophils." J Toxicol Sci 27(3): 191-203. 
18. Narita . Hypotensive and diuretic actions of diltiazem in spontaneously hypertensive and 
Wistar Kyoto  rats.. The Journal of pharmacology and experimental therapeutics. 
1983;227(2):472. 
19. Noguchi . Antitumor Activity of a Novel Chimera Tumor Necrosis Factor (TNF-STH) 
Constructed by Connecting rTNF-S with Thymosin [beta] 4 Against Murine Syngeneic 
Tumors. Journal of immunotherapy (1997). 1991;10(2):105. 
20. O'Connor SE. The pharmacological basis and pathophysiological significance of the heart 
rate-lowering  property of diltiazem. Fundamental & clinical pharmacology. 1999 
Mar;13(2):145-153. 
21. Peixoto . Reproducibility of ambulatory blood pressure monitoring in hemodialysis 
patients. American journal of kidney diseases. 2000;36(5):983. 
22. Perel . Systolic blood pressure variation is a sensitive indicator of hypovolemia in 
ventilated dogs subjected to graded hemorrhage. Anesthesiology (Philadelphia). 
1987;67(4):498 
23. Saunders . A comparison of the efficacy and safety of a {beta}-blocker, a calcium 
channel blocker, and a  converting enzyme inhibitor in hypertensive blacks. 
Archives of internal medicine (1960).  1990;150(8):1707. 
24. Shou Y, Jan, Kung-ming., and Rumschitzki, David. Transport in rat vessel walls. II. 
Macromolecular leakage and focal spot size growth in rat arteries and veins. American 
Journal of Physiology 292: H2881–H2890, 2007. 
39 
 
25. Stemerman MB, Morre, E.M.,Burke, K.R., Colton, C.K., Smith, K. A., and Lees, R. S.,. 
Local variation in arterial wall permeability to Low Density Lipoprotein in normal rabbit 
aorta. Atherosclerosis 6: 64-69, 1986. 
26. Toussaint, Jimmy Deon. Aquaporin-1 and pressure-driven water transport across aortic 
endothelia. Aquaporin-1 expression, distribution and regulation. United States -- New 
York: Engineering; 2009. (PhD thesis) 
27. Tsutsumi . Molecular design of hybrid tumor necrosis factor-alpha III: polyethylene 
glycol-modified tumor necrosis factor-alpha has markedly enhanced antitumor potency 
due to longer plasma half-life and higher tumor accumulation.. The Journal of 
pharmacology and experimental therapeutics. 1996;278(3):1006. 
28. Verbin, R. S., D. S. Longnecker, H. Liang and E. Farber (1971). "Some observations on 
the acute histopathologic effects of cycloheximide in vivo." Am J Pathol 62(1): 111-25. 
29. Weinbaum S, Tzeghai, G., Ganatos, P., Pfeffer, R., and Chien, S. Effect of cell turnover 
and leaky junctions on arterial macromolecular transport. Am J of Physiol 248: H945-
H960, 1985. 
30. Wolinsky . Long-term effects of hypertension on the rat aortic wall and their relation to 
concurrent aging changes: morphological and chemical studies. Circulation research. 
1972;30(3):301. 
31. Yao E. Effects of the Antioxidative Beta-Blocker Celiprolol on Endothelial Progenitor 
Cells in Hypertensive  Rats. American journal of hypertension. 2008 Sep;21(9):1062-
1068. 
32. Yu Sun. The focal spread of macromolecular tracers in vessel walls: Frequency and effect 
of intima compaction and blood pressure. United States -- New York: Engineering; 2008. 
(PhD thesis) 
33. Zahn, G. and A. Greischel (1989). "Pharmacokinetics of tumor necrosis factor alpha after 
intravenous administration in rats. Dose dependence and influence of tumor necrosis 
factor beta." Arzneimittelforschung 39(9): 1180-2. 
34. Carmichael. Nembutal anesthesia III. The median lethal dose of Nembutal (pentobarbital 
sodium) for young and old rats. The Journal of pharmacology and experimental 
therapeutics. 1938;62(3):284. 
35. http://www.avma.org/issues/animal_welfare/euthanasia_guidelines/species-lab-small-
and-wild-caught-rodents.asp 
